ASNR Statement on Gadolinium-Based Contrast Agent Use in Patients with Chronic Kidney Disease.

Autor:	Welker KM; From the Department of Radiology, Mayo Clinic, Rochester MN, USA (K.M.W), Department of Radiology and Medical Imaging, University of Virginia, Charlottesville, VA, USA (D.J.), Department of Radiology, Loyola University Medical Center, Maywood, IL, USA (A.W.K), Department of Neurology, University of California Los Angeles, Los Angeles, CA, USA (D.S.L.), Department of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, GA, USA (A.M.S., C.S), Department of Radiology and Nuclear Medicine, University of Maryland School of Medicine, Baltimore, MD, USA (N.Y.), and Department of Radiology, Providence Little Company of Mary Medical Center, Torrance, CA, USA (J.E.J.)., Joyner D; From the Department of Radiology, Mayo Clinic, Rochester MN, USA (K.M.W), Department of Radiology and Medical Imaging, University of Virginia, Charlottesville, VA, USA (D.J.), Department of Radiology, Loyola University Medical Center, Maywood, IL, USA (A.W.K), Department of Neurology, University of California Los Angeles, Los Angeles, CA, USA (D.S.L.), Department of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, GA, USA (A.M.S., C.S), Department of Radiology and Nuclear Medicine, University of Maryland School of Medicine, Baltimore, MD, USA (N.Y.), and Department of Radiology, Providence Little Company of Mary Medical Center, Torrance, CA, USA (J.E.J.)., Kam AW; From the Department of Radiology, Mayo Clinic, Rochester MN, USA (K.M.W), Department of Radiology and Medical Imaging, University of Virginia, Charlottesville, VA, USA (D.J.), Department of Radiology, Loyola University Medical Center, Maywood, IL, USA (A.W.K), Department of Neurology, University of California Los Angeles, Los Angeles, CA, USA (D.S.L.), Department of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, GA, USA (A.M.S., C.S), Department of Radiology and Nuclear Medicine, University of Maryland School of Medicine, Baltimore, MD, USA (N.Y.), and Department of Radiology, Providence Little Company of Mary Medical Center, Torrance, CA, USA (J.E.J.)., Liebeskind DS; From the Department of Radiology, Mayo Clinic, Rochester MN, USA (K.M.W), Department of Radiology and Medical Imaging, University of Virginia, Charlottesville, VA, USA (D.J.), Department of Radiology, Loyola University Medical Center, Maywood, IL, USA (A.W.K), Department of Neurology, University of California Los Angeles, Los Angeles, CA, USA (D.S.L.), Department of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, GA, USA (A.M.S., C.S), Department of Radiology and Nuclear Medicine, University of Maryland School of Medicine, Baltimore, MD, USA (N.Y.), and Department of Radiology, Providence Little Company of Mary Medical Center, Torrance, CA, USA (J.E.J.)., Saindane AM; From the Department of Radiology, Mayo Clinic, Rochester MN, USA (K.M.W), Department of Radiology and Medical Imaging, University of Virginia, Charlottesville, VA, USA (D.J.), Department of Radiology, Loyola University Medical Center, Maywood, IL, USA (A.W.K), Department of Neurology, University of California Los Angeles, Los Angeles, CA, USA (D.S.L.), Department of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, GA, USA (A.M.S., C.S), Department of Radiology and Nuclear Medicine, University of Maryland School of Medicine, Baltimore, MD, USA (N.Y.), and Department of Radiology, Providence Little Company of Mary Medical Center, Torrance, CA, USA (J.E.J.)., Segovis C; From the Department of Radiology, Mayo Clinic, Rochester MN, USA (K.M.W), Department of Radiology and Medical Imaging, University of Virginia, Charlottesville, VA, USA (D.J.), Department of Radiology, Loyola University Medical Center, Maywood, IL, USA (A.W.K), Department of Neurology, University of California Los Angeles, Los Angeles, CA, USA (D.S.L.), Department of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, GA, USA (A.M.S., C.S), Department of Radiology and Nuclear Medicine, University of Maryland School of Medicine, Baltimore, MD, USA (N.Y.), and Department of Radiology, Providence Little Company of Mary Medical Center, Torrance, CA, USA (J.E.J.)., Yahyavi-Firouz-Abadi N; From the Department of Radiology, Mayo Clinic, Rochester MN, USA (K.M.W), Department of Radiology and Medical Imaging, University of Virginia, Charlottesville, VA, USA (D.J.), Department of Radiology, Loyola University Medical Center, Maywood, IL, USA (A.W.K), Department of Neurology, University of California Los Angeles, Los Angeles, CA, USA (D.S.L.), Department of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, GA, USA (A.M.S., C.S), Department of Radiology and Nuclear Medicine, University of Maryland School of Medicine, Baltimore, MD, USA (N.Y.), and Department of Radiology, Providence Little Company of Mary Medical Center, Torrance, CA, USA (J.E.J.)., Jordan JE; From the Department of Radiology, Mayo Clinic, Rochester MN, USA (K.M.W), Department of Radiology and Medical Imaging, University of Virginia, Charlottesville, VA, USA (D.J.), Department of Radiology, Loyola University Medical Center, Maywood, IL, USA (A.W.K), Department of Neurology, University of California Los Angeles, Los Angeles, CA, USA (D.S.L.), Department of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, GA, USA (A.M.S., C.S), Department of Radiology and Nuclear Medicine, University of Maryland School of Medicine, Baltimore, MD, USA (N.Y.), and Department of Radiology, Providence Little Company of Mary Medical Center, Torrance, CA, USA (J.E.J.).
Jazyk:	angličtina
Zdroj:	AJNR. American journal of neuroradiology [AJNR Am J Neuroradiol] 2024 Sep 16. Date of Electronic Publication: 2024 Sep 16.
DOI:	10.3174/ajnr.A8501
Abstrakt:	Background: Beginning in 2006, neuroradiologists became increasingly aware of the risk of nephrogenic system fibrosis (NSF) when patients suffering from chronic kidney disease (CKD) received gadolinium-based contrast agents (GBCAs) in conjunction with MRI scans. Radiology practices began withholding GBCAs from MRI patients with substantial CKD and instated a variety of safety measures to ensure that these individuals did not inadvertently receive GBCAs. As a result, the worldwide incidence of NSF was dramatically reduced. Since that time, a wealth of research on NSF and its etiology has found few unconfounded cases associated with those GBCAs categorized as Group II agents by the American College of Radiology. Methods: In 2023 and 2024, members of the American Society of Neuroradiology (ASNR) Standards and Guidelines Committee reviewed new research evidence on GBCA safety and its relevance to current MRI contrast administration guidelines for patients with CKD. This focused on systematic reviews and meta-analyses conducted during the past five years. Upon consideration of this literature, recommendations for administration of GBCAs to patients with CKD were formulated. Key Message: For neuroimaging applications, the ASNR recommends that Group II GBCAs no longer be withheld in patients with CKD when these agents are medically indicated for diagnosis. Moreover, if Group II GBCAs are exclusively used in an MRI practice, other safety measures such as checking renal function or querying patients about chronic kidney disease can be discontinued. Abbreviations: ACR = American College of Radiology; ASNR = American Society of Neuroradiology; CKD = chronic kidney disease; GBCA = gadolinium-based contrast agent; NSF = nephrogenic systemic fibrosis. Competing Interests: C.S. has served as an expert witness on the topic of MRI safety. K.M.W., D.J., A.W.K., D.S.L., A.M.S., N.Y., and J.E.J. declare no conflicts of interest related to the content of this article. (© 2024 by American Journal of Neuroradiology.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu